Integra LifeSciences Holdings Corporation $IART Shares Sold by Vanguard Group Inc.

Vanguard Group Inc. lessened its stake in shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) by 2.6% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,379,127 shares of the life sciences company’s stock after selling 199,166 shares during the quarter. Vanguard Group Inc. owned approximately 9.47% of Integra LifeSciences worth $105,743,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also modified their holdings of the company. Public Sector Pension Investment Board increased its stake in shares of Integra LifeSciences by 14.7% during the 3rd quarter. Public Sector Pension Investment Board now owns 261,347 shares of the life sciences company’s stock valued at $3,745,000 after acquiring an additional 33,526 shares during the last quarter. Savant Capital LLC purchased a new stake in Integra LifeSciences in the third quarter valued at approximately $288,000. Envestnet Asset Management Inc. acquired a new position in Integra LifeSciences during the third quarter worth approximately $190,000. Allianz Asset Management GmbH raised its stake in Integra LifeSciences by 88.7% during the third quarter. Allianz Asset Management GmbH now owns 433,738 shares of the life sciences company’s stock worth $6,215,000 after purchasing an additional 203,834 shares during the period. Finally, State of Wyoming boosted its holdings in Integra LifeSciences by 22.2% in the third quarter. State of Wyoming now owns 15,830 shares of the life sciences company’s stock valued at $227,000 after acquiring an additional 2,877 shares during the last quarter. Hedge funds and other institutional investors own 84.78% of the company’s stock.

Integra LifeSciences Price Performance

Shares of NASDAQ IART opened at $10.39 on Thursday. The company has a debt-to-equity ratio of 1.66, a current ratio of 2.54 and a quick ratio of 1.46. The firm has a market capitalization of $809.80 million, a PE ratio of -1.54 and a beta of 1.02. Integra LifeSciences Holdings Corporation has a 1-year low of $9.96 and a 1-year high of $24.36. The business’s fifty day moving average price is $11.83 and its two-hundred day moving average price is $13.12.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings results on Thursday, February 26th. The life sciences company reported $0.83 EPS for the quarter, topping the consensus estimate of $0.79 by $0.04. The business had revenue of $434.93 million during the quarter, compared to analyst estimates of $429.62 million. Integra LifeSciences had a negative net margin of 31.58% and a positive return on equity of 14.76%. The company’s quarterly revenue was down 1.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.97 earnings per share. Integra LifeSciences has set its Q1 2026 guidance at 0.370-0.450 EPS and its FY 2026 guidance at 2.300-2.400 EPS. On average, research analysts expect that Integra LifeSciences Holdings Corporation will post 2.45 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on IART shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Integra LifeSciences in a research report on Monday, December 29th. Wells Fargo & Company decreased their price target on Integra LifeSciences from $13.00 to $12.00 and set an “equal weight” rating for the company in a report on Friday, February 27th. Finally, Wall Street Zen upgraded shares of Integra LifeSciences from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. Two equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Reduce” and a consensus target price of $14.80.

Integra LifeSciences Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.